Fig. 4.
Forest plot of NMA for adverse events (AEs) of first-line systemic treatments for advanced HCC compared to atezolizumab plus bevacizumab. a grade ≥3 (severe) AEs (SAEs). b AEs leading to treatment discontinuation.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.